The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.